Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis

Background: Mycobacterium tuberculosis [Mtb] could be present in different metabolic population in the lung lesions, and nonreplicating persisters [NRP], associated with latent tuberculosis [TB], are the most difficult to kill. Objective: Test the combination of tedizolid, moxifloxacin, and faropene...

Descripción completa

Detalles Bibliográficos
Autores principales: Srivastava, Shashikant, Cirrincione, Kayle N., Deshpande, Devyani, Gumbo, Tawanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851080/
https://www.ncbi.nlm.nih.gov/pubmed/33542690
http://dx.doi.org/10.3389/fphar.2020.616294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851080/
https://www.ncbi.nlm.nih.gov/pubmed/33542690
http://dx.doi.org/10.3389/fphar.2020.616294

Ejemplares similares